title: Biomarker research with prospective study designs for the early detection of cancer.
abstract: This article describes the principles of marker research with prospective studies along with examples for diagnostic tumor markers. A plethora of biomarkers have been claimed as useful for the early detection of cancer. However, disappointingly few biomarkers were approved for the detection of unrecognized disease, and even approved markers may lack a sound validation phase. Prospective studies aimed at the early detection of cancer are costly and long-lasting and therefore the bottleneck in marker research. They enroll a large number of clinically asymptomatic subjects and follow-up on incident cases. As invasive procedures cannot be applied to collect tissue samples from the target organ, biomarkers can only be determined in easily accessible body fluids. Marker levels increase during cancer development, with samples collected closer to the occurrence of symptoms or a clinical diagnosis being more informative than earlier samples. Only prospective designs allow the serial collection of pre-diagnostic samples. Their storage in a biobank upgrades cohort studies to serve for both, marker discovery and validation. Population-based cohort studies, which may collect a wealth of data, are commonly conducted with just one baseline investigation lacking serial samples. However, they can provide valuable information about factors that influence the marker level. Screening programs can be employed to archive serial samples but require significant efforts to collect samples and auxiliary data for marker research. Randomized controlled trials have the highest level of evidence in assessing a biomarker's benefit against usual care and present the most stringent design for the validation of promising markers as well as for the discovery of new markers. In summary, all kinds of prospective studies can benefit from a biobank as they can serve as a platform for biomarker research. This article is part of a Special Issue entitled: Biomarkers: A Proteomic Challenge.
authors.affiliation: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Germany. Electronic address: pesch@ipa-dguv.de.
authors.forename: B
authors.initials: B
authors.lastname: Pesch
authors.affiliation: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Germany; Protein Research Unit Ruhr within Europe (PURE), Ruhr University Bochum, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Brüning
authors.affiliation: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Johnen
authors.affiliation: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Casjens
authors.affiliation: Protein Research Unit Ruhr within Europe (PURE), Ruhr University Bochum, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Bonberg
authors.affiliation: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Taeger
authors.affiliation: Protein Research Unit Ruhr within Europe (PURE), Ruhr University Bochum, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Müller
authors.affiliation: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Germany.
authors.forename: D G
authors.initials: DG
authors.lastname: Weber
authors.affiliation: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Germany; Protein Research Unit Ruhr within Europe (PURE), Ruhr University Bochum, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Behrens
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D035843:Biomedical Research; D055088:Early Detection of Cancer; D006801:Humans; D009363:Neoplasm Proteins / Q000378:metabolism*; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D011446:Prospective Studies; D040901:Proteomics / Q000379:methods*; D012107:Research Design
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins
keywords: Bias; Diagnostic marker; Prospective study; Screening; Study design; Validation